Congress:
ECR25
Poster Number:
C-27870
Type:
Poster: EPOS Radiologist (scientific)
Authorblock:
A. Iozzelli, A. Cipriani, L. Costarelli; Macerata/IT
Disclosures:
Andrea Iozzelli:
Nothing to disclose
Antonio Cipriani:
Nothing to disclose
Leonardo Costarelli:
Nothing to disclose
Keywords:
Breast, Contrast agents, Oncology, MR, Biopsy, Cancer
- Bashir MR, Thomas KL. A New Generation of Gadolinium-based MRI Contrast Agents: Higher Relaxivity, Lower Dose. Radiology. 2023 Jul;308(1):e231454. doi: 10.1148/radiol.231454.
- Kuhl C, Csőszi T, Piskorski W, Miszalski T, Lee JM, Otto PM. Efficacy and Safety of Half-Dose Gadopiclenol versus Full-Dose Gadobutrol for Contrast-enhanced Body MRI. Radiology. 2023 Jul;308(1):e222612. doi: 10.1148/radiol.222612.
- Robert P, Vives V, Grindel AL, et al. Contrast-to-Dose Relationship of Gadopiclenol, an MRI Macrocyclic Gadolinium-based Contrast Agent, Compared with Gadoterate, Gadobenate, and Gadobutrol in a Rat Brain Tumor Model. Radiology. 2020 Jan;294(1):117-126. doi: 10.1148/radiol.2019182953.
- Foshag K, Tsiouris AJ, Prince M, Reichman M. A review of gadolinium-based contrast agents in the setting of repeated MRI for high risk breast cancer screening. Clin Imaging. 2025 Feb 3;120:110420. doi: 10.1016/j.clinimag.2025.110420. Epub ahead of print.